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FUS is a DNA/RNA binding protein found to be mutated
in some cases of both sporadic and familial forms of ALS.
It is still not clear how ALS-causing mutations in FUS
leads to motor neuron degeneration. Here, we exploited
a Drosophila model and mammalian neuronal cell lines
to elucidate the role of the RNA-binding ability of FUS in
regulating FUS-mediated toxicity. To determine the role
of the RNA binding ability of FUS in ALS, we mutated
FUS RNA binding sites (F305, F341, F359, F368) to leu-
cines and generated RNA binding-incompetent mutants
(4F-L) with and without ALS causing mutations R518K
or R521C. We found that mutating 4F to L residues
makes FUS RNA binding-incompetent. We observed
that ectopic expression of RNA binding-incompetent
FUS in fly brain, eyes and motor neurons strongly blocks
neurodegenerative phenotypes as compared to RNA-
binding-competent FUS carrying ALS causing mutations.
Interestingly, RNA-binding deficient FUS strongly localized
to the nucleus of Drosophila motor neurons and mam-
malian neuronal cells whereas FUS carrying ALS linked
mutations was distributed to the nucleus and cytoplasm.
Importantly, we found that incorporation of mutant
FUS into stress granules is dependent on the RNA-binding
ability of FUS. SGs are dynamic aggregates composed of
proteins and RNA that are formed when cells are under a
variety of stresses. We observed that normally cytoplasmic
SGs rapidly disassemble when stress conditions end,
whereas cytoplasmic SGs formed in ALS patient cells
having a FUS mutation fail to disassemble. This suggests
that mutant FUS sequesters proteins and RNAs important
for cellular homeostasis and the defect in disassembly of
cytoplasmic SGs contributes to ALS. Finally, following up
these observations we performed an in vivo unbiased
genetic screen that led to the discovery of several domi-
nant modifiers of mutant FUS toxicity including proteins
involved in regulating SG dynamics, mitochondrial func-
tions and RNA splicing. These genetic modifiers would
help in identifying potential therapeutic targets for ALS.
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